ImmunityBio (IBRX) reported significant commercial momentum for its key product, ANKTIVA, which drove total revenue to \(75.0M YTD (a 976% increase from \)7.2M in the prior year). Net Loss narrowed substantially to \((289.5M)\) YTD, and diluted EPS loss improved to \((0.32)\) from \((0.53)\).
Liquidity and Capital Structure: Total cash and marketable securities stood at \(257.8M, although cash and equivalents declined to \)60.2M, reflecting capital deployment into \(197.6M of marketable U.S. Treasury securities. The company maintains a Stockholders’ Deficit, totaling approximately \)(524.3M)$. Substa
...